Anbio Unveils Advanced Veterinary Diagnostics at WSAVA 2025

Anbio Biotechnology showcased its latest veterinary diagnostic portfolio during the 50th World Small Animal Veterinary Association Congress (WSAVA 2025) held in Rio de Janeiro on October 9, 2025. The congress, which attracted veterinarians, researchers, and industry representatives from over 100 countries, served as a significant platform for Anbio to engage with stakeholders and highlight innovations in veterinary healthcare.

At the event, Anbio presented five distinct product lines that generated considerable interest among attendees. The company’s dry chemiluminescence and fluorescence immunoassay systems were particularly praised for their precision and user-friendly design. Discussions with distributors revealed a strong demand for accessible and accurate testing technologies, which are essential for advancing veterinary healthcare.

A standout feature of Anbio’s presentation was its molecular diagnostics platform, which can deliver multi-target real-time PCR results in just 15 minutes. This rapid testing capability is crucial for the timely detection of respiratory and infectious diseases in animals, enhancing clinical management and improving outcomes. Delegates noted the importance of such technologies in bolstering outbreak response efforts and streamlining routine diagnostic workflows.

The exhibition also provided Anbio with opportunities to connect with existing and potential partners, discussing distribution strategies and future product rollouts. These conversations underscored the growing significance of point-of-care diagnostics in veterinary practice and highlighted the necessity of international collaboration to expand access to these vital tools.

Looking ahead, Anbio plans to continue its global outreach. The company will participate in the Wild West Vet Show 2025, scheduled for October 15–18, 2025, in Reno, Nevada, USA. This upcoming exhibition will further enable Anbio to present its veterinary diagnostic solutions and engage with professionals in the North American market.

Anbio Biotechnology is dedicated to advancing both human and veterinary diagnostics. By developing practical and reliable testing solutions, the company plays a critical role in improving healthcare outcomes across various settings worldwide.

Founded with a commitment to enhancing the availability of reliable diagnostics, Anbio offers a diverse range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing, and veterinary diagnostics. Its operations span multiple regions, reflecting a strong focus on supporting better decision-making in healthcare environments globally.